Zeke Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Zeke Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$563K	Buy	780 +292	+60%	+$215K	0.04%	224
2022 Q3	$337K	Buy	488 +10	+2%	+$6.29K	0.02%	289
2022 Q2	$283K	Buy	478 +19	+4%	+$12.3K	0.02%	342
2022 Q1	$320K	Buy	+459	New	+$290K	0.02%	354
2020 Q1	–	Sell	-1,263	Closed	-$474K	–	455
2019 Q4	$474K	Buy	1,263 +34	+3%	+$11.4K	0.04%	392
2019 Q3	$341K	Buy	1,229 +6	+0.5%	+$1.77K	0.03%	427
2019 Q2	$383K	Sell	1,223 -55	-4%	-$18.3K	0.04%	419
2019 Q1	$525K	Sell	1,278 -832	-39%	-$343K	0.05%	345
2018 Q4	$788K	Sell	2,110 -2,073	-50%	-$759K	0.08%	244
2018 Q3	$1.69M	Buy	4,183 +11	+0.3%	+$4.19K	0.14%	127
2018 Q2	$1.44M	Buy	+4,172	New	+$1.3M	0.13%	126
2017 Q4	–	Sell	-799	Closed	-$357K	–	606
2017 Q3	$357K	Hold	799	–	–	0.05%	291
2017 Q2	$392K	Buy	+799	New	+$350K	0.08%	160

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Zeke Capital Advisors's REGN Position: Q4 2022 in Review

Zeke Capital Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 60% in Q4 2022, buying an estimated $215K and bringing the position to 780 shares worth $563K. The position accounts for 0.04% of the portfolio, ranked #224.

Zeke Capital Advisors first reported a position in REGN in Q2 2017 and has held it in 13 quarters since. The position peaked at $1.69M in Q3 2018. 1,160 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Zeke Capital Advisors held 780 shares of Regeneron Pharmaceuticals worth $563K as of Q4 2022.
Zeke Capital Advisors bought 292 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $215K.
Regeneron Pharmaceuticals made up 0.04% of Zeke Capital Advisors's portfolio in Q4 2022, its #224 holding.
Zeke Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2017 and has held it in 13 quarters since.
Zeke Capital Advisors's Regeneron Pharmaceuticals position peaked at $1.69M in Q3 2018.
1,160 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.